At Stemnovate, we integrate advanced bioinformatics with our cellular platform to identify biomarkers that can help diagnose liver and heart diseases or neurodegenerative diseases early.
RAPID DIAGNOSTICS
Stemnovate developed a revolutionary High Fidelity Isothermal Nucleic Acid Amplification technology on a chip. It promises rapid sensitive and specific diagnosis of infectious, inherited and genetic diseases with the potential to overcome the drawbacks identified in conventional PCR for field application and mass testing. It has greater amplification efficiency and produces higher DNA yields than PCR owing to its undisrupted and sustained enzyme activity.
EARLY DIAGNOSIS OF HEART CONDITIONS
The diagnosis of heart failure is difficult in the early stages or before a constellation of physical signs and symptoms associated with the process appear. This leads to delayed diagnosis and increases the risk of complications. Heart failure is becoming a significant non-communicable disease leading to death in ageing and young individuals globally.
We have dedicated ourselves to finding biomarkers to characterise and understand heart disease and other research that can contribute to early diagnosis.
NEW DIAGNOSTICS ASSAYS
Our strength is in molecular sciences and bioinformatics. We develop novel technology and partner with companies to improve stringency for existence assays and better controls, saving cost and time. Our lab follows rigorous screening protocols to make sure you obtain reliable diagnostic results.